Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2Thoracic 1Sarcoma 1Lymphoid 1Gastrointestinal 1

Conditions

Gliosarcoma 43Glioblastoma 43Brain Neoplasms 29Glioma 23Sarcoma 20Astrocytoma 13Oligodendroglioma 10Central Nervous System Neoplasms 8Colorectal Neoplasms 7Neoplasm Metastasis 6Recurrence 5Stomach Neoplasms 4Neoplasms 4Hemangiosarcoma 4Carcinoma, Hepatocellular 4Sarcoma, Kaposi 3Ovarian Neoplasms 3Osteosarcoma 3Gastrointestinal Stromal Tumors 3Sarcoma, Ewing 2Sarcoma, Alveolar Soft Part 2Rhabdomyosarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Melanoma 2Lymphoma, Non-Hodgkin 2Leiomyosarcoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Diffuse Intrinsic Pontine Glioma 2

Interventions

surufatinib 1ganitumab 1conatumumab 1Quality of Life 1Patient Reported Outcome Measures 1Molecular Diagnostic Techniques 1Immunotherapy 1Drug Therapy 1Dacarbazine 1Bortezomib 1Biological Therapy 1Biological Factors 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoid Tumor × Bevacizumab × Sarcoma × Clear all
NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Amgen

Phase 2 Completed
12 enrolled 21 charts
EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡